{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:36:03Z","timestamp":1773358563169,"version":"3.50.1"},"reference-count":37,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Actinic keratosis is a common, chronic, and potentially pre-cancerous skin disease that can negatively impact patients\u2019 health-related quality of life. This systematic review aimed to identify and describe the questionnaires used to assess health-related quality of life in patients with actinic keratosis and summarize reported impacts. Four databases (EMBASE, PsycINFO, PubMed, and Cochrane Library) were searched up to February 2025. Two reviewers independently screened articles, and risk of bias was assessed using tools appropriate to study design. Of 639 records, 37 studies including 9,326 patients met inclusion criteria. Most studies were interventional (59%) and of moderate to high quality (64%). Health-related quality of life was assessed using 3 disease-specific, 3 dermatology-specific, and 2 generic questionnaires. The most frequently used instruments were the Actinic Keratosis Quality of Life (n\u2009=\u200913) and the Dermatology Life Quality Index (n\u2009=\u200916). All questionnaires detected health-related quality of life impairment, especially during treatment. Actinic Keratosis Quality of Life identified patient subgroups with greater health-related quality of life reduction, including females, younger individuals, patients with comorbidities, and those with a history of skin cancer. All health-related quality of life questionnaires captured impairment in patients with actinic keratosis. The Actinic Keratosis Quality of Life and Dermatology Life Quality Index questionnaires were widely used. Actinic Keratosis Quality of Life identified subpopulations with health-related quality of life impairment. Among studies reporting mean health-related quality of life scores, the Dermatology Life Quality Index ranged from 1.55 to 24 and the Actinic Keratosis Quality of Life from 4.22 to 17, reflecting very broad variability and underlying differences in actinic keratosis severity across study populations.<\/jats:p>","DOI":"10.2340\/actadv.v106.44163","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:38:47Z","timestamp":1773319127000},"page":"adv44163","source":"Crossref","is-referenced-by-count":0,"title":["Health-related Quality of Life Measurements in Patients with Actinic Keratosis: A Systematic Review"],"prefix":"10.2340","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7675-4844","authenticated-orcid":false,"given":"Zohra F.","family":"Ahmadzay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-2248","authenticated-orcid":false,"given":"Mattias A.S.","family":"Henning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0712-2540","authenticated-orcid":false,"given":"Gregor B.E.","family":"Jemec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4485-702X","authenticated-orcid":false,"given":"Gabrielle R.","family":"Vinding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"144338","doi-asserted-by":"crossref","unstructured":"Malvehy J, Stratigos AJ, Bagot M, Stockfleth E, Ezzedine K, Delarue A. Actinic keratosis: current challenges and unanswered questions. J Eur Acad Dermatol Venereol 2024; 38(Suppl. 5): 3\u201311.","DOI":"10.1111\/jdv.19559"},{"key":"144339","doi-asserted-by":"crossref","unstructured":"de Oliveira ECV, da Motta VRV, Pantoja PC, Ilha CS de O, Magalh\u00e3es RF, Galadari H, Leonardi GR. Actinic keratosis \u2013 review for clinical practice. Int J Dermatol 2019; 58(4): 400\u2013407.","DOI":"10.1111\/ijd.14147"},{"key":"144340","doi-asserted-by":"crossref","unstructured":"Esmann S. Patients\u2019 perspectives on actinic keratosis. Curr Probl Dermatol (Switzerland) 2015; 46: 8\u201313.","DOI":"10.1159\/000366530"},{"key":"144341","doi-asserted-by":"crossref","unstructured":"Esmann S, Jemec GBE. Management of actinic keratosis patients: a qualitative study. J Dermatol Treat2007; 18(1): 53\u201358.","DOI":"10.1080\/09546630601028737"},{"key":"144342","doi-asserted-by":"crossref","unstructured":"Finlay AY, Salek MS, Abeni D, Tom\u00e1s-Aragon\u00e9s L, van Cranenburgh OD, Evers AWM, et al. Why quality of life measurement is important in dermatology clinical practice. J Eur Acad Dermatol Venereol 2017; 31: 424\u2013431.","DOI":"10.1111\/jdv.13985"},{"key":"144343","doi-asserted-by":"crossref","unstructured":"Chernyshov PV, Lallas A, Tomas-Aragones L, Arenbergerova M, Samimi M, Manolache L, et al. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. J Eur Acad Dermatol Venereol 2019; 33: 816\u2013827.","DOI":"10.1111\/jdv.15487"},{"key":"144344","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372.","DOI":"10.1136\/bmj.n71"},{"key":"144345","doi-asserted-by":"crossref","unstructured":"Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary. Mil Med Res. Military Medical Research 2020; 7: 1\u201311. Available from: https:\/\/mmrjournal.biomedcentral.com\/track\/pdf\/10.1186\/s40779-020-00238-8.pdf","DOI":"10.1186\/s40779-020-00238-8"},{"key":"144346","doi-asserted-by":"crossref","unstructured":"Olsen EA, Lisa Abernethy M, Kulp-Shorten C, Callen JP, Glazer SD, Huntley A, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol; 1991; 24: 738\u2013743.","DOI":"10.1016\/0190-9622(91)70113-G"},{"key":"144347","doi-asserted-by":"crossref","unstructured":"Esmann S, Vinding GR, Christensen KB, Jemec GBE. Assessing the influence of actinic keratosis on patients\u2019 quality of life: the AKQoL questionnaire. Br J Dermatol 2013; 168(2): 277\u2013283.","DOI":"10.1111\/bjd.12036"},{"key":"144348","doi-asserted-by":"crossref","unstructured":"Longo I, Serra-Guill\u00e9n C. Quality of life, behaviour and attitudes towards actinic keratosis in Spain: the PIQA study. Actas Dermosifiliogr 2018; 109: 331\u2013339.","DOI":"10.1016\/j.adengl.2018.01.003"},{"key":"144349","doi-asserted-by":"crossref","unstructured":"Tennvall GR, Norlin JM, Malmberg I, Erlendsson AM, H\u00e6dersdal M. Health related quality of life in patients with actinic keratosis: an observational study of patients treated in dermatology specialist care in Denmark. Health Qual Life Outcomes 2015; 13: 1\u20139.","DOI":"10.1186\/s12955-015-0295-4"},{"key":"144350","doi-asserted-by":"crossref","unstructured":"Neri L, Peris K, Longo C, Calvieri S, Frascione P, Parodi A, Actinic Keratosis \u2013 TReatment Adherence INitiative (AK-TRAIN) study group. Physician\u2013patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy or the treatment of actinic keratosis in Italy. J Eur Acad Dermatol Venereol 2019; 33: 93\u2013107.","DOI":"10.1111\/jdv.15142"},{"key":"144351","doi-asserted-by":"crossref","unstructured":"Norrlid H, Norlin JM, Holmstrup H, Malmberg I, Sartorius K, Thormann H, et al. Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients. J Dermatolog Treat 2018; 29: 68\u201373.","DOI":"10.1080\/09546634.2017.1329514"},{"key":"144352","doi-asserted-by":"crossref","unstructured":"Vis K, Waalboer-Spuij R, Snels DGCTM, Hollestein LM. Validity and reliability of the Dutch adaptation of the Actinic Keratosis Quality of Life Questionnaire (AKQoL). Dermatology 2018; 234: 60\u201365.","DOI":"10.1159\/000489118"},{"key":"144353","doi-asserted-by":"crossref","unstructured":"Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope 2007; 117: 399\u2013405.","DOI":"10.1097\/MLG.0b013e31802e2d88"},{"key":"144354","doi-asserted-by":"crossref","unstructured":"Hasan ZU, Ahmed I, Matin RN, Homer V, Lear JT, Ismail F, et al. Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments). Br J Dermatolo 2022; 18: 324\u2013337.","DOI":"10.1111\/bjd.20974"},{"key":"144355","doi-asserted-by":"crossref","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210\u2013216.","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"144356","doi-asserted-by":"crossref","unstructured":"Hongbo Y, Thomas CL, Harrison MA, Sam Salek M, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Investig Dermatol 2005; 125: 659\u2013664.","DOI":"10.1111\/j.0022-202X.2005.23621.x"},{"key":"144357","doi-asserted-by":"crossref","unstructured":"Tejada C dos S, Mendoza-Sassi RA, Almeida Jr HL de, Figueiredo PN, Tejada VF dos S. Impact on the quality of life of dermatological patients in southern Brazil. An Bras Dermatol 2011; 86: 1113\u20131121.","DOI":"10.1590\/S0365-05962011000600008"},{"key":"144358","doi-asserted-by":"crossref","unstructured":"Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001; 5: 105\u2013110.","DOI":"10.1007\/BF02737863"},{"key":"144359","doi-asserted-by":"crossref","unstructured":"Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433\u20131440.","DOI":"10.1001\/archderm.1997.03890470111018"},{"key":"144360","doi-asserted-by":"crossref","unstructured":"Nijsten TEC, Sampogna F, Chren MM, Abeni DD. Testing and reducing Skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol 2006; 126: 1244\u20131250.","DOI":"10.1038\/sj.jid.5700212"},{"key":"144361","doi-asserted-by":"crossref","unstructured":"Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 2012; 30: 231\u2013236.","DOI":"10.1016\/j.det.2011.11.003"},{"key":"144362","doi-asserted-by":"crossref","unstructured":"Nijsten T, Sampogna F, Abeni D. Categorization of Skindex-29 scores using mixture analysis. Dermatology 2009; 218(2): 151\u2013154.","DOI":"10.1159\/000182253"},{"key":"144363","doi-asserted-by":"crossref","unstructured":"Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence 2013; 8: 35\u201341.","DOI":"10.2147\/PPA.S47126"},{"key":"144364","doi-asserted-by":"crossref","unstructured":"Waalboer-Spuij R, Holterhues C, Van Hattem S, Schuttelaar MLA, Gaastra MTW, Kuijpers DIM, et al. Patient perception of imiquimod treatment for actinic keratosis and superficial basal cell carcinoma in 202 patients. Dermatology 2015; 231: 56\u201362.","DOI":"10.1159\/000381420"},{"key":"144365","unstructured":"EuroQol Research Foundation. EQ-5D-5L User Guide 2019 (Version 3.0). Available from: EuroQol Research Foundation. EQ-5D-5L User Guide 2019 (Version 3.0)."},{"key":"144366","doi-asserted-by":"crossref","unstructured":"Philipp-Dormston WG, M\u00fcller K, Novak B, Str\u00f6mer K, Termeer C, Hammann U, NMSC-QoL Study Group. Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression. J Eur Acad Dermatol Venereol 2018; 32: 1138\u20131146.","DOI":"10.1111\/jdv.14703"},{"key":"144367","unstructured":"RAND Health Care 20-Item Short Form Survey (SF-20) [Internet] [accessed 2025-01-29]. Available from: https:\/\/www.rand.org\/health-care\/surveys_tools\/mos\/20-item-short-form.html"},{"key":"144368","doi-asserted-by":"crossref","unstructured":"Thomas SI, Taylor MA, Plampton K, Sharma D, Samson KK, Wysong A, et al. Assessing quality of life in field cancerization: an institutional cohort analysis. Dermatol Surg 2024; 50: 1202\u20131203.","DOI":"10.1097\/DSS.0000000000004311"},{"key":"144369","doi-asserted-by":"crossref","unstructured":"Anthony E, Lun K, Smith SD. Full face ingenol mebutate for actinic keratosis: patient perspective. Int J Dermatol 2019; 58: e6\u2013e9.","DOI":"10.1111\/ijd.14263"},{"key":"144370","doi-asserted-by":"crossref","unstructured":"Hanke WC, Norlin JM, Mark Knudsen K, Larsson T, Stone S. Quality of life in treatment of AK: treatment burden of ingenol mebutate gel is small and short lasting. J Dermatol Treat 2016; 27: 450\u2013455.","DOI":"10.3109\/09546634.2016.1160024"},{"key":"144371","doi-asserted-by":"crossref","unstructured":"Gholam P, Kroehl V, Enk AH. Dermatology life quality index and side effects after topical photodynamic therapy of actinic keratosis. Dermatology 2013; 226: 253\u2013259.","DOI":"10.1159\/000349992"},{"key":"144372","doi-asserted-by":"crossref","unstructured":"R\u0103ducu L, Avino A, Purtan RP, Balcangiu-Stroescu AE, Bal\u0103n DG, Timofte D, et al. Quality of life in patients with surgically removed skin tumors. Medicina (Lithuania) 2020; 56: 3\u20139.","DOI":"10.3390\/medicina56020066"},{"key":"144373","doi-asserted-by":"crossref","unstructured":"Prinsen CAC, de Korte J, Augustin M, Sampogna F, Salek SS, Basra MKA, EADV Taskforce on Quality of Life. Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. J Eur Acad Dermatol Venereol 2013; 27: 1195\u2013203.","DOI":"10.1111\/jdv.12090"},{"key":"144374","doi-asserted-by":"crossref","unstructured":"Grada A, Feldman SR, Bragazzi NL, Damiani G. Patient-reported outcomes of topical therapies in actinic keratosis: a systematic review. Dermatol Ther 2021; 34: 1\u201310.","DOI":"10.1111\/dth.14833"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/44163\/53139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/44163\/53139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:39:08Z","timestamp":1773319148000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/44163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":37,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.44163","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}